AIR-POWER 200 MG — DIN 02229984
GUAIFENESIN : 200 MG · ENZYMATIC THERAPY (CANADA) INC. · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is AIR-POWER?
AIR-POWER 200 MG contains GUAIFENESIN : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02229984, held by ENZYMATIC THERAPY (CANADA) INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 08-Aug-2002. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
How much does Guaifenesin cost around the world?
Guaifenesin is listed on 7 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory); Iceland publishes a max wholesale. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 15 | 15 | SAR███.██ |
| United States | acquisition | 3 | 5 | USD███.██ |
| South Africa | single exit price | 3 | 4 | ZAR███.██ |
| United Arab Emirates | public | 3 | 3 | AED███.██ |
| Bahrain | retail (max) | 2 | 2 | BHD███.██ |
| Czechia | max producer price (ex-factory) | 1 | 1 | CZK███.██ |
| Iceland | max wholesale | 1 | 1 | ISK███.██ |
31 pack listings across 28 brand entries and 6 price bases, refreshed 03 Sep 2026. Ranges span every Guaifenesin pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Guaifenesin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
31 holders have a Canadian DIN containing Guaifenesin, across 59 DINs, of which 10 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | 4 | 3 | BENYLIN CHEST CONGESTION EXTRA STRENGTH, BENYLIN EXTRA STRENGTH CHEST CONGESTION & COLD, BENYLIN EXTRA STRENGTH MUCUS & PHLEGM, BENYLIN EXTRA STRENGTH SORE THROAT & COUGH | Sourceable in Canada |
| HALEON CANADA ULC | 3 | 3 | BUCKLEY'S CHEST CONGESTION, BUCKLEY'S MUCUS & PHLEGM, ROBITUSSIN EXTRA STRENGTH MUCUS AND PHLEGM | Sourceable in Canada |
| TEVA CANADA LIMITED | 6 | 1 | BALMINIL EXPECTORANT, BALMINIL EXPECTORANT (SUCROSE FREE), EXPECTORANT SYRUP, EXPECTORANT SYRUP (SUCROSE FREE), EXTRA STRENGTH MUCOUS RELIEF CHEST, +1 more | Sourceable in Canada |
| CRLS | 3 | 1 | CHEST CONGESTION & COLD EXTRA STRENGTH, MUCUS & PHLEGM RELIEF EXTRA STRENGTH, SORE THROAT & COUGH EXTRA STRENGTH | Sourceable in Canada |
| LABORATOIRE ATLAS INC | 1 | 1 | BRONCHOPHAN EXPECTORANT (SANS SUCROSE) | Sourceable in Canada |
| RB HEALTH (CANADA) INC. | 1 | 1 | MUCINEX CHEST CONGESTION | Sourceable in Canada |
| TECHNILAB PHARMA INC. | 4 | 0 | CALMYLIN EXPECTORANT SYR 100MG/5ML, EXPECTORANT COUGH SYRUP 100MG/5ML, KOFFEX EXPECTORANT, KOFFEX EXPECTORANT SANS SUCROSE | No marketed DIN |
| CELLCHEM PHARMACEUTICALS INC. | 3 | 0 | CHEST CONGESTION, CHEST CONGESTION SYRUP, MUCUS & PHLEGM SYRUP | No marketed DIN |
| ROUGIER PHARMA DIVISION OF RATIOPHARM INC | 3 | 0 | BALMINIL EXPECTORANT LIQ 100MG/5ML, GUAIFENESINE LIQ 100MG/5ML, GUAIFENESINE LIQ 100MG/5ML SANS SUCROSE | No marketed DIN |
| STANLEY PHARMACEUTICALS, A DIVISION OF VITA HEALTH PRODUCTS INC. | 3 | 0 | COUGH SYRUP EXPECTORANT, EXTRA STRENGTH COUGH SYRUP EXPECTORANT, TUSSIN COUGH MEDICINE GF EXPECTORANT | No marketed DIN |
| TRILLIUM HEALTH CARE PRODUCTS INC | 3 | 0 | EXPECTORANT (EXTRA STRENGTH) SYRUP, EXPECTORANT (REGULAR STRENGTH) COUGH SYRUP, MUCUS & PHLEGM RELIEF EXTRA STRENGTH | No marketed DIN |
| PROCTER & GAMBLE INC | 2 | 0 | VICKS CHEST CONGESTION RELIEF, VICKS DAYQUIL MUCUS CONTROL | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 200 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Guaifenesin |
|---|---|
| ATC code | R05CA03 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02229984 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2229984 |
| Brand name | AIR-POWER |
| Generic / active ingredient | GUAIFENESIN : 200 MG |
| Market authorization holder | ENZYMATIC THERAPY (CANADA) INC. |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| ATC code | R05CA03 |
| ATC anatomical main group | R — Respiratory system |
| ATC therapeutic subgroup | R05CA |
| Current status | CANCELLED POST MARKET |
| Status date | 08-Aug-2002 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
10 of 59 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| BALMINIL EXPECTORANT (SUCROSE FREE) | 100 MG / 5 ML | SYRUP | TEVA CANADA LIMITED | MARKETED | 00609951 |
| BENYLIN EXTRA STRENGTH CHEST CONGESTION & COLD | 15 MG / 5 ML | SYRUP | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | 02265427 |
| BENYLIN EXTRA STRENGTH MUCUS & PHLEGM | 15 MG / 5 ML | SYRUP | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | 02320940 |
| BENYLIN EXTRA STRENGTH SORE THROAT & COUGH | 200 MG / 5 ML | SYRUP | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | 02479869 |
| BRONCHOPHAN EXPECTORANT (SANS SUCROSE) | 100 MG / 5 ML | SYRUP | LABORATOIRE ATLAS INC | MARKETED | 02121999 |
| BUCKLEY'S CHEST CONGESTION | 100 MG / 5 ML | SYRUP | HALEON CANADA ULC | MARKETED | 02289164 |
| BUCKLEY'S MUCUS & PHLEGM | 100 MG / 5 ML | SYRUP | HALEON CANADA ULC | MARKETED | 02346451 |
| MUCINEX CHEST CONGESTION | 600 MG | TABLET (IMMEDIATE AND EXTENDED RELEASE) | RB HEALTH (CANADA) INC. | MARKETED | 02434725 |
| MUCUS & PHLEGM RELIEF EXTRA STRENGTH | 200 MG / 5 ML | SYRUP | CRLS | MARKETED | 02534762 |
| ROBITUSSIN EXTRA STRENGTH MUCUS AND PHLEGM | 200 MG / 5 ML | SYRUP | HALEON CANADA ULC | MARKETED | 02142783 |
2 · Same class — other molecules in ATC R05CA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Guaifenesin | AIR-POWER · BALMINIL EXPECTORANT · BALMINIL EXPECTORANT (SUCROSE FREE) · BALMINIL EXPECTORANT LIQ 100MG/5ML · +50 more | 59 | 10 | Yes |
| Combinations | ALSIDRINE LIQ · BABYS OWN COUGH SYR · BISMUTAL ADULTS · BRONCH EZE · +37 more | 42 | 4 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC R05C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| R05CB | Acetylcysteine · Dornase Alfa (Desoxyribonuclease) | 11 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is AIR-POWER called?
The same molecule, Guaifenesin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Respinol Expecorant | Latin | South Africa |
| ACTIFED EXPECTORANT SYRUP | Latin | Saudi Arabia |
| Benylin Bronchospect | Latin | South Africa |
| Flusin Expectorant Syrup | Latin | South Africa |
| GUAFEDRIN | Latin | Saudi Arabia |
| GUAJACURAN | Latin | Czechia |
| GUAPHAN | Latin | Saudi Arabia |
| GUAPHAN DM | Latin | Saudi Arabia |
| MUCINEX | Latin | Bahrain |
| Mucinex® | Latin | United Arab Emirates |
| Myorelax | Latin | Iceland |
| PECTOMED | Latin | Bahrain |
| PECTOMED EXPECTORANT SYRUP | Latin | Saudi Arabia |
| ROBITUSSIN CF SYRUP | Latin | Saudi Arabia |
| ROBITUSSIN SYRUP | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.